Ovarian cancer combo shows promise in maintenance therapy
NCT ID NCT06121401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-line treatment will receive the combination as maintenance therapy. The study aims to confirm how well this approach works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olaparib (Lynparza) and bevacizumab
What this could lead to
If successful, this could confirm that combining olaparib with bevacizumab helps keep advanced ovarian cancer from coming back longer after initial treatment.
What could go wrong
This is a phase IV trial confirming real-world use, not a new breakthrough. Results may show limited benefit or side effects like fatigue, nausea, or high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. Ordine Mauriziano
Torino, Italy
-
A.O.U. Citta della Salute e della Scienza
Torino, Italy
-
AOU Parma
Parma, Italy
-
Arcispedale Santa Maria Nuova
Reggio Emilia, Italy
-
Azienda Socio Sanitaria Territoriale (ASST) Lariana
San Fermo della Battaglia, Como, 22042, Italy
-
Istituto Europeo di Oncologia
Milan, Italy
-
Istituto Nazionale dei Tumori
Milan, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, 35128, Italy
-
Ospedale Manzoni
Lecco, Italy
-
Ospedale San Luca
Lucca, Italy
-
Ospedale Santa Chiara
Pisa, Italy
-
Ospedale Umberto I
Roma, Italy
-
Policlinico Careggi
Florence, Italy
-
Spedali Civili
Brescia, Italy